Study Design and setting: This single-blind randomized clinical trial was done from February 2019 to March 2020 in a NICU of academic center (Rouhani Hospital, Babol, Iran).
Participant: Preterm infants 28-37 weeks of gestation, who have to be vaccinated for hepatitis B –zero turn the vaccine- were randomly assigned to three groups. The inclusion criteria were infants with no painful procedure and no feeding for up to one hour before the intervention, stability in vital signs, no head and skull abnormalities as well as no receiving painkillers, sedatives and anticonvulsants. The exclusion criteria were maternal withdrawal from the study and infant sever disease or death.
Sample size: Considering 80% power and 0.05 error probability in this study, the number of cases was determined to be at least 30 neonates in each group [2].
Data collection and processing: According to the ward's schedule during the first four days of life, injection of HB vaccine was done. Preterm neonate was placed on a warmer by servo control and skin temperature 36.5- 37◦C in quiet room. All conditions including room temperature (25◦C), light, injection device were the same for all three groups as well as the vaccine administration was done by one person. The researcher and nurse did not use any aromatic substances in vaccination room during the study. The probe of monitoring was placed on the right wrist of baby without applying additional pressure. Heart rate, blood pressure and SaO2 of all preterm infants were recorded before starting the intervention as the initial time and immediately after completing vaccination (using the standard pulse oximeter and ECG monitoring of Saadat Company, Iran).
In both groups of A and B, the breast milk samples taken in the early morning before eating breakfast were used to stimulate the smell sense of neonates. Pouring 2 ml of maternal breast milk and another mother’s breast milk on a cotton swab was done as an intervention, and 2 ml of distilled water as control group (group C). Next, these swabs were placed three centimeters away from the baby's nose. This process started 3 min before vaccination and continued until the vaccination was completed [2].
Pain measurement
The Premature Infant Pain Profile (PIPP) was used as the primary outcome variable. PIPP scores were recorded immediately before and after the vaccination for each infant. The PIPP is a behavioral measure of pain for premature infants. It includes seven indicators: 1) gestational age, 2) the behavioral state, 3) change in heart rate, 4) change in oxygen saturation, 5) brow bulge; 6) eyes squeeze and 7) nasolabial furrow. The total score is the summation of all seven indicators, with a minimum of 0 and maximum of 21; the higher the score, the greater the pain behavior [14]. If the overall PIPP score is between 0 and 6 points, the pain level is mild; if between 7 and 12 points, it is moderate; and if between 13 and 21 points, it is severe [15] The PIPP tool was revised and validated for use with preterm babies born at 26-37 weeks of gestation by Gibbins et al. in 2014 [16]
Video recording of behavioral responses was taken from the beginning to the end of the process by a trained nurse, and then PIPP scoring was performed through watching video by the first author. The scoring was done while the video viewer was unaware of the test group. Throughout the intervention, any actions on the neonates such as contact, movement and so on were avoided.
Data were collected by using the demographic questionnaire including: birth weight, current disease (respiratory distress syndrome, transient tachypnea of newborn, sepsis and very low birth weight) , sex, gestational age, postnatal age, Apgar score and PIPP score.
Data analysis: Statistics advisor performed the data analysis blindly by using SPSS Version 18. Descriptive information was shown as frequency, percentage, mean and standard deviation. Chi-square test for the relationship between two qualitative variables (demographic and PIPP qualitative variables with group variable), ANOVA test for comparing quantitative variables at the levels of more than two variables (quantitative demographic variables with group variable) and ANCOVA test for comparing research outcomes (SBP, DBP, SaO2 and heart rate) were used to remove the pretest effect and a P value< 0.05 were considered significant.
Ethical consideration
The study protocol was approved by the Ethics Committees of Babol University of Medical Sciences (IR.MUBABOL.REC.1397.253). The trial is registered in the IRCT20190220042771N1 Before participation in the study, written informed consent was obtained from each child’s primary guardian.